Compare WSBC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WSBC | GPCR |
|---|---|---|
| Founded | 1870 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 1994 | 2023 |
| Metric | WSBC | GPCR |
|---|---|---|
| Price | $42.17 | $53.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $39.25 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 870.6K | 483.2K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $23.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.57 | $18.26 |
| 52 Week High | $43.02 | $94.90 |
| Indicator | WSBC | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 55.29 |
| Support Level | $38.53 | $43.76 |
| Resistance Level | N/A | $57.15 |
| Average True Range (ATR) | 0.62 | 2.49 |
| MACD | -0.10 | 0.21 |
| Stochastic Oscillator | 51.64 | 68.64 |
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.